We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
226
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$524K 0.03%
215
– –
REE
227
DELISTED
RARE ELEMENT RES LTD
REE
$519K 0.03%
3,436,858
-407,015
-11% -$89.8K
PGNX
228
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$515K 0.03%
840
– –
SUNE
229
CALL
DELISTED
SUNEDISON, INC COM
SUNE
$509K 0.03%
1,000
– –
ALBO
230
DELISTED
Albireo Pharma Inc
ALBO
$507K 0.03%
49,358
+16,569
+51% +$171K
SCON
231
DELISTED
Superconductor Technologies Inc.
SCON
$493K 0.03%
1,567
+1,036
+195% +$384K
TPST icon
232
CALL
Tempest Therapeutics
TPST
$14.3M
– –
0
– –
VPCO
233
DELISTED
VAPOR CORP DEL COM STK
VPCO
$487K 0.03%
+901,608
New +$346K
EW icon
234
Edwards Lifesciences
EW
$49.4B
$482K 0.03%
18,321
-445,209
-96% -$11.6M
SAGE
235
DELISTED
Sage Therapeutics
SAGE
$474K 0.03%
8,123
-31,896
-80% -$1.58M
ALDX icon
236
Aldeyra Therapeutics
ALDX
$97.1M
$466K 0.03%
68,699
-66,298
-49% -$446K
CSLT
237
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$455K 0.03%
+106,500
New +$457K
LPCN icon
238
CALL
Lipocine
LPCN
$17.1M
$453K 0.02%
+21
New +$4.41K
RGLS
239
PUT
DELISTED
Regulus Therapeutics
RGLS
$436K 0.02%
+4
New +$4.01K
ESPR
240
DELISTED
Esperion Therapeutics
ESPR
$423K 0.02%
19,000
-4,990
-21% -$126K
TXMD icon
241
PUT
TherapeuticsMD
TXMD
$23.8M
$419K 0.02%
+8
New +$2.95K
SAGE
242
CALL
DELISTED
Sage Therapeutics
SAGE
$414K 0.02%
71
-180
-72% -$8.92K
OCGN icon
243
Ocugen
OCGN
$403M
$412K 0.02%
1,961
+1,503
+328% +$336K
ASRT
244
PUT
DELISTED
Assertio
ASRT
$408K 0.02%
+4
New +$4.5K
AFMD
245
DELISTED
Affimed
AFMD
$404K 0.02%
5,677
– –
PGEN icon
246
PUT
Precigen
PGEN
$1.94B
$404K 0.02%
135
– –
THMO
247
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$387K 0.02%
236
-153
-39% -$623K
CLDX icon
248
PUT
Celldex Therapeutics
CLDX
$2.94B
$373K 0.02%
16
– –
ALXN
249
DELISTED
Alexion Pharmaceuticals
ALXN
$373K 0.02%
1,956
-47,441
-96% -$8.29M
NWBO
250
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$373K 0.02%
1,165
-4,877
-81% -$23.5K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.